A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)

PHASE2Enrolling by invitationINTERVENTIONAL
Enrollment

332

Participants

Timeline

Start Date

September 30, 2019

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
Acute Myeloid LeukemiaChronic Myelomonocytic LeukemiaMyelodysplastic Syndromes
Interventions
DRUG

ASTX727

ASTX727 film-coated, immediate-release FDC tablets

Trial Locations (48)

1130

Wiener Gesundheitsverbund - Klinik Hietzing 06 FE Study, Vienna

Wiener Gesundheitsverbund - Klinik Hietzing 06 Study, Vienna

1797

Specialized Hospital for Active Treatment of Hematological Disease EAD, Sofia

4000

Complex Oncology Center - Plovdiv - Base II, Plovdiv

4032

Debreceni Egyetem Klinikai Kozpont, Belgyogyszati Klinika, B epulet, Hematologia, Debrecen

14263

Rosewell Park Cancer Institute, Buffalo

Roswell Park Cancer Institute - 06 FE Study, Buffalo

20122

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan

21231

The Sidney Kimmel Comprehensive Cancer Center at John Hopkins, Baltimore

22328

Institutul Oncologic Bucuresti - Prof. Dr. Alexandru Trestioreanu, Bucharest

23538

Universitätsklinikum Schleswig-Holstein - Campus Lübeck, Lübeck

28027

Clínica Universidad de Navarra - Madrid, Madrid

28041

Hospital Universitario 12 de Octubre, Madrid

29414

Charleston Hematology Oncology Associates, Charleston

30120

Hospital Clínico Universitario Virgen de la Arrixaca, Murcia

33322

Boca Raton Clinical Research, Plantation

37232

Vanderbilt - Ingram Cancer Center, Nashville

38114

Städtisches Klinikum Braunschweig, Braunschweig

44718

Gabrail Cancer Center Research - 06 FE Study, Canton

Gabrail Cancer Center Research, Canton

46026

Hospital Universitario La Fe, Valencia

49503

Cancer and Hematology Centers for Western Michigan, Grand Rapids

55905

Mayo - Rochester, Rochester

60637

The University of Chicago Medical Center, Chicago

68100

Hôpital Emile Muller, Mulhouse

75246

Baylor Scott White University Medical Center, Dallas

75390

University of Texas Southwestern Medical Center, Dallas

77030

The University of Texas MD Anderson Cancer Center, Houston

78229

May Cancer Center, San Antonio

83101

Summit Clinical Research s.r.o, Bratislava

92708

Compassionate Care Research Group, Fountain Valley

92739

Oregon Health and Science University, Portland

98109

Seattle Cancer Care Alliance/Fred Hutchinson Cancer Research Center, Seattle

99336

Kadlec Clinic Hematology and Oncology, Kennewick

400015

Institutul Oncologic Prof. Dr. Ion Chiricuta, Cluj-Napoca

07601

Hackensack Medical Center - 06 FE Study, Hackensack

Hackensack Medical Center, Hackensack

Unknown

Erebuni Medical Center, Yerevan

Hematology Center After Prof. R. Yeolyan (Adult Blood Disorders), Yerevan

Hematology Center After Prof. R. Yeolyan (Clinic of Adults Oncology), Yerevan

National Center of Oncology Named After V.A. Fanarjyan, Yerevan

Centrum Badań Klinicznych Piotr Napora Lekarze Sp. p., Wroclaw

Hospital Universitari Arnau de Vilanova, Lleida

T6G 2B7

University of Alberta Hospital, Edmonton

B3H 2Y9

QEII Health Sciences Centre, Nova Scotia

K1H 8L6

The Ottawa Hosptial, Ottawa

M4N 3M5

Sunnybrook Health Sciences Centre, Toronto

M5G 2M9

Princess Margaret Cancer Center, Toronto

All Listed Sponsors
lead

Taiho Oncology, Inc.

INDUSTRY

NCT04093570 - A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) | Biotech Hunter | Biotech Hunter